Skip to content
Company Terminals IPO Intel Calculators Gold Desk Research Services Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus

Prasol Chemicals

PRASOLCHEM · Chemicals · INE455U01024

Analyst mean 0.00 · 0 analysts · 0% bullish
₹704.75
Close 2026-09-22 · Balanced risk
Price
₹704.75
Mkt cap
₹4,196 cr
P/E (TTM)
47.5xexcl. exceptional items
P/B
8.81x
Book value
₹75.4
ROE
17.5%
Op margin
9.7%
Net margin
6.7%
D/E
0.25
Consolidatedstandalone figures are read separately and never mixed into these tables

What's newsince the last filing we processed

Announcement 22 Sep - Board meeting on September 28, 2026 to approve Q1 FY27 unaudited financial results. Open
Credit rating 10 Jun 2015 Open

Read from the offer document

This company listed within the last twelve months, so its prospectus is still the primary source. The figures below were extracted from the DRHP and RHP before listing and scored then, and they are shown here as they stand in the IPO record rather than restated.

55/100 100% coverage
₹676 Mainboard
₹500 cr
-9.8%

What the score is made of

Score components
Issue structure58
Filing integrity34
Financial quality86.1
Valuation vs peers40
Underwriter quality60
Governance forensics32

Flagged in the offer document

Each flag is a fact read in the filing, shown with the context that makes it meaningful.

  • IPO Expenses Held as Asset (Deferred Capitalization) noted
  • Excess Managerial Remuneration flagged
  • Weaknesses in Internal Financial Controls flagged
  • Missing/Untraceable Corporate Records flagged
  • Criminal Complaints Against Managing Director flagged
  • Land Transaction with Promoter noted

What the issue was raised for

Stated objects, as worded in the offer document. Deployment against them is tracked separately.

  • Source: p. 188 · Purpose: Repayment or pre-payment, in full or in part, of certain of our outstanding borrowings availed by our Company · Amount cr: 60
  • Source: p. 188 · Purpose: General corporate purposes

What the company said

Claims made in the offer document, to be read against what the company has reported since.

  • No defaults or rescheduling/restructuring of borrowings with financial institutions/banks
  • All related party transactions are on an arm's length basis and in compliance with applicable law
  • No material litigation that could adversely affect operations

Lock-in

  • Period: 3 years · Source: p. 182 · Category: Promoter Minimum Contribution · Pct of total: 20
  • Period: 1 year · Source: p. 182 · Category: Promoter Excess Shareholding
  • Period: 6 months · Source: p. 183 · Category: Pre-Offer Capital (Other than Promoter Contribution)

The business

What it does

Deep

Prasol Chemicals Limited, established in 1992, is a leading forward-integrated manufacturer of acetone and phosphorus-based specialty chemicals, as well as other customized specialty chemicals involving complex and differentiated chemistries. The company operates two automated manufacturing facilities in Khopoli and Mahad, Maharashtra, with an aggregate installed capacity of 98,644 metric tonnes per annum as of June 30, 2026. The company’s comprehensive product portfolio includes over 150 specialty chemical products, consisting of 21 acetone-based specialty chemicals (such as diacetone alcohol, isophorone, and hexylene glycol), 53 phosphorus-based specialty chemicals (such as phosphorus pentasulphide and polyphosphoric acid), and 76 other customized specialty products (including surfactants, performance additives, ethers, esters, polymers, and acids). Prasol is the sole manufacturer of isophorone in India with a capacity of 9,000 MTPA. It caters to a highly diversified customer base of 1,618 customers in Fiscal 2026 across major application industries including performance chemicals, paints, inks, construction and adhesives (PICA), pharmaceuticals, agrochemicals, and home and personal care. The company possesses a robust global footprint, exporting to 69 countries across the Asia-Pacific region, North America, South America, and Europe. It is also the largest importer of acetone and among the top five importers and users of yellow phosphorus in India.

Moat

Prasol's competitive moat is driven by its position as the sole manufacturer of isophorone in India (9,000 MTPA capacity) and the largest importer and consumer of acetone in India, resulting in limited domestic competition. Additionally, the industry has high entry barriers, including a lengthy customer registration and qualification process of 1-4 years, and the company benefits from strong application-driven R&D capabilities and backward integration.

Short

Prasol Chemicals Limited is a forward integrated manufacturer of acetone and phosphorus-based specialty chemicals, as well as other specialty chemicals involving complex and differentiated chemistries. Established in 1992, the company serves a diversified customer base across domestic and international markets, exporting to 69 countries as of July 15, 2026.

Source: p. 237, p. 289

Revenue segments

Where the revenue came from, as the document splits it.

Pct
Acetone based specialty chemicals42.8%
Phosphorous based specialty chemicals38.3%
Other specialty chemicals18.3%
Other operating and service revenue0.62%
The numbers behind it
NamePctSource
Acetone based specialty chemicals42.75p. 302
Phosphorous based specialty chemicals38.3p. 302
Other specialty chemicals18.33p. 302
Other operating and service revenue0.62p. 302
The industry

Summary

The global chemicals industry expanded to USD 6.2 trillion in CY25 and is projected to reach USD 7.8 trillion by CY29, with the specialty chemicals segment expected to reach a 21-23% market share. The global specialty chemicals market was valued at USD 1,240 billion in CY25 and is projected to reach USD 1,748 billion by CY29, growing at a CAGR of 9.0%. Domestically, the Indian specialty chemicals market reached ₹ 5,563 billion in FY26 and is projected to grow at a CAGR of 10-12% to reach ₹ 7,541 billion by FY29. This growth is propelled by domestic consumption, rising exports, and expanding application industries such as pharmaceuticals, agrochemicals, home care, and performance chemicals.

Growth rate: 10-12%

Market size: ₹ 5,56,300 Crore

Sector slug: specialty-chemicals

Source: p. 232

Peers named in the document

The comparable set the company chose, which is itself a disclosure.

NameMarginPbPeRoeSource
Aarti Industries LimitedEBITDA Margin: 14.17%, PAT Margin: 5.06%46.79p. 202, p. 206
Atul LimitedEBITDA Margin: 16.53%, PAT Margin: 10.99%28.04p. 202, p. 206
Laxmi Organic Industries LimitedEBITDA Margin: 6.01%, PAT Margin: 2.79%59.95p. 202, p. 206
Vinati Organics LimitedEBITDA Margin: 29.36%, PAT Margin: 19.93%30.95p. 202, p. 206
Privi Speciality Chemicals LimitedEBITDA Margin: 25.21%, PAT Margin: 12.35%42.67p. 202, p. 206
Yasho Industries LimitedEBITDA Margin: 17.04%, PAT Margin: 3.04%206.68p. 202, p. 206
Excel Industries LimitedEBITDA Margin: 12.06%, PAT Margin: 6.91%17.12p. 202, p. 206

The numbers as filed

Financials

As presented in the offer document. Post-listing figures are in the statements above.

Revenue crPat cr
87718.1
FY24
1,01243.6
FY25
1,23383.1
FY26
The questions worth asking

Written before listing, answered from the document itself.

Why is a cash-rich firm with ₹ 24.07 crore of cash on hand raising ₹ 80 crore in fresh equity, and why is most of the ₹ 500 crore issue an Offer for Sale (OFS)?

The fresh issue is ₹ 80 crore, out of which ₹ 60 crore is allocated to repay existing term loans to optimize debt-equity ratios and save on interest costs (which stood at ₹ 7.98 crore in FY26). The remaining ₹ 420 crore is an OFS by the promoters and promoter group, allowing them to cash out a portion of their holdings (they hold 89.20% pre-offer) without the funds flowing back to the company for capital investment.

p. 87, p. 188

What is the extent of supplier concentration risk for Prasol's raw materials, and who are these suppliers?

Supplier concentration is extremely high. The top 10 suppliers accounted for 68.87% (₹ 474.13 crore) of the raw materials consumed in FY26, and the top 3 suppliers accounted for 39.75% (₹ 273.69 crore). Crucially, the names of these top suppliers are omitted from the RHP due to 'commercial sensitivities of disclosure.' null of them are disclosed as related parties.

p. 58, p. 302

Why did the company's EBITDA margins drop in FY25 compared to peer averages, and is the recovery in FY26 sustainable?

Profitability is highly sensitive to raw material import costs (acetone and yellow phosphorus). In FY25, margins were compressed due to raw material price escalation. While standalone Operating EBITDA margins recovered to 11.30% in FY26, this is still significantly lower than peers like Vinati (29.36%) and Privi (25.21%), and any future supply chain disruption or rupee depreciation poses a major threat to sustainability.

p. 203, p. 206

What are the material regulatory and operational compliance risks arising from the multiple toxic gas leaks and safety audits?

The company has a history of toxic leaks at its Mahad plant, including a chlorine leak on August 9, 2023, and a hydrogen sulphide (H2S) leak on October 5, 2023, which resulted in fatalities and hospitalizations. These have led to 6 pending criminal cases against Managing Director Gaurang Natwarlal Parikh and show-cause notices from DISH and MPCB. Any adverse court ruling or repeat incident could result in permanent plant shutdowns and criminal liabilities.

p. 22, p. 32, p. 471

Valuation at issue

What the issue priced at, on the figures in the document.

Pe basis: Based on Basic and Diluted EPS for the financial year ended March 31, 2026. Cap vs Floor not finalised.

Peer set note

Consists of specialty chemical players Aarti, Atul, Laxmi Organic, Vinati, Privi Speciality, Yasho, and Excel, irrespective of variation in P/E.

Source: p. 201

The offer, ownership and risks

Subscription

How the book filled. A category that bid far above the rest is a different signal from a uniformly covered issue.

Overall subscription, by day
10-09-20263.83x
09-09-20260.52x
08-09-20260.49x
Final book, by category
Retail0.7x
Non-institutional0.93x
QIB0x
Reservation
2721614
388802
1555209
Pre-IPO investors
DateNameSharesPrice per shareCategorySource
1993-02-25Initial Subscription and Further Issue15000010Various subscribersp. 111
1994-04-01Further Issuance35000010Various subscribersp. 111
1995-02-21Further Issuance20000010Various subscribersp. 111
1995-03-16Further Issuance50000010Various subscribersp. 111
1996-02-23Further Issuance110850010Various subscribersp. 111
2002-03-07Buy back-13521130Company buy backp. 111
2003-10-13Buy back-32580030Company buy backp. 111
2004-03-01Buy back-10073230Company buy backp. 111
2007-07-12Rights issue (1:4)43669050Rights issuep. 111
2009-12-10Rights issue (1:4)54586260Rights issuep. 111
2012-02-21Rights issue (2:15)363908125Rights issuep. 111
2016-10-17Private Placement6783400Private Placementp. 111
2017-07-12Buy back-200000400Company buy backp. 111
2021-12-08Stock Split (Sub-division 1:5)11600000Sub-divisionp. 111
Management

Ceo: Gaurang Natwarlal Parikh

Litigation

Outstanding litigation against the Company includes 9 tax cases (direct tax: 4 cases of ₹ 0.57 crore; indirect tax: 5 cases of ₹ 3.78 crore), 16 statutory/regulatory proceedings (aggregate ₹ 6.18 crore) and 1 material civil litigation (₹ 1.24 crore). Outstanding litigation against Promoters includes 6 criminal proceedings, 4 tax proceedings (₹ 2.80 crore) and 1 statutory/regulatory proceeding (all against Gaurang Natwarlal Parikh except 1 police complaint against Pankil Nishith Dharia with a fine of ₹ 1,250). Outstanding litigation against Directors includes 2 direct tax cases (₹ 0.60 crore).

Auditor name: C N K & Associates LLP

Skin in game

As of the date of the RHP, the Promoters and Promoter Group collectively hold 51,735,560 Equity Shares constituting 89.20% of the pre-Offer issued, subscribed and paid-up Equity Share capital.

Auditor rpt flags

The Statutory Auditors' report on the Audited Financial Statements for FY26 and Audited Consolidated Financial Statements for FY25 and FY24 contains emphasis of matter regarding IPO expenses of ₹ 2.92 crore in FY26 and excess managerial remuneration of ₹ 2.24 crore in FY24, along with modified opinions on internal financial controls over financial reporting regarding inventory records and overhead allocation for all three years.

Auditor changed last 3y: No

Source: p. 2, p. 32, p. 74, p. 466, p. 472

Related-party dealings

Transactions with promoters, directors and their entities, as disclosed.

CounterpartyAmount crNatureRelationshipCore functionSource
Nishith R Shah4.582Directors remuneration and remuneration payablePromoter and ChairmanExecutive Managementp. 98
Gaurang N Parikh3.237Directors remuneration and remuneration payablePromoter and Managing DirectorExecutive Managementp. 98
Dhaval Nalin Parikh4.41Purchase of a land parcel on January 20, 2022, adjoining Khopoli facilityPromoter and Joint Managing DirectorCompliance with green belt environmental clearance requirementsp. 346
Heat Fabs (Firm)0.72Purchase of Stores & Consumables and EquipmentsEnterprise over which relative of KMP has controlSupply chain and capital equipment procurementp. 97
Statutory dues

Detail

Delays in depositing Employee Provident Fund (EPF) contributions: 3 instances in FY26 (negligible amount), 2 instances in FY25 (₹ 0.006 crore), and 2 instances in FY24 (₹ 0.007 crore) due to ERP system design deficiencies, Aadhaar linking/KYC errors, EPFO portal technical issues, and banking payment glitches. Outstanding MSME dues of ₹ 3.50 crore and undisputed other trade payables of ₹ 204.73 crore are recorded as of March 31, 2026.

Defaults disclosed: Yes

Source: p. 51, p. 52, p. 90

What changed between DRHP and RHP

A change between the two filings is a disclosure in itself.


  • Reporting periods updated to reflect the full financial year 2026 as Standalone (since the sole subsidiary was struck off) and historical comparative periods.

  • RHP updated with complete audited Standalone financial statements for the year ended March 31, 2026. Overlapping year figures (FY25 and FY24) remained consistent with DRHP.

  • Total OFS size remained ₹ 420.00 Crore. Due Jatin Narendra Parikh's passing on August 24, 2026, their shares were not transmitted, and both Jatin Narendra Parikh and Chamak Jatin Parikh were removed as selling shareholders, with their allocations redistributed.

  • Aggregate contingent liabilities increased from ₹ 8.52 Crore in June 2025 to ₹ 10.02 Crore in March 2026, driven primarily by higher unhedged bank guarantees and DRI customs claims.

  • Risk factors were reordered to prioritize and bring critical operational facility-dependency and environmental/safety risks (such as toxic gas leaks and industrial accidents) to the front.

  • While the borrowing repayment object allocation remained ₹ 60.00 Crore, the evaluation date of loans and prepayment penalty terms (up to 2% p.a.) were updated to reflect July 15, 2026.

  • Tax disputes against the Company decreased from 13 to 9, while statutory proceedings increased. Criminal cases against Promoters increased from 5 to 6 due to a new summary criminal case filed by the Deputy Director of Industrial Safety & Health (DISH) on October 14, 2025.

  • Disclosures on statutory dues payments (provident fund deposits) were updated with revised counts and delayed amounts as per the updated audit reports.
Timeline
2026-09-07
2026-09-08
2026-09-10
2026-09-11
2026-09-15
2026-09-15
2026-09-16
2026-10-22
The offer and who ran it
Ownership around the issue
Promoter, pre-issue89.2%
Pledged0%
80 cr
420 cr
89.2%
0%
2
22
14,872
p. 187, No
KFin Technologies Limited
DAM Capital Advisors Limited

Price in context split-adjusted

Close 50-DMA 200-DMA

Numbered markers are corporate actions and, once the filings are read, capital and governance events. Prices are split-adjusted so the series is continuous.

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Cash lags profit somewhat

Operating cash is 59% of trailing profit — a modest gap worth keeping an eye on.

Why this reading: Noted with caution: a mild gap that is commonly benign (working-capital timing) but worth tracking across years.

Full read

Operating cash ₹49 cr vs trailing profit ₹83 cr. Gaps in the 0.5–0.9 range are usually timing, occasionally a early tell.

Net margin compressing

Net margin has narrowed from 9.3% to 6.7% year-on-year — profitability per rupee of sales is shrinking.

Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.

Full read

Quarter net margin 6.7% vs 9.3% four quarters earlier. Sustained compression signals pricing pressure, cost inflation, or mix deterioration.

Free cash flow is variable

Free cash flow swings between positive and negative across the cycle.

Why this reading: Surfaced for context, not as a concern — it only becomes meaningful if it persists or pairs with other signals.

Full read

Latest ₹11 cr, negative in 2 of 6 years.

Forensic modelscomputed from the filed statements

Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.

Altman Z″

Needs current assets and current liabilities.

Piotroski F

7 / 8 1 not testable
  • Profitable this year
  • Operating cash positive
  • Return on assets improved
  • Cash exceeds profit
  • Leverage reduced
  • Liquidity improved
  • No share dilution
  • Margin improved
  • Assets working harder
What is this, and how do I read it?

Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.

Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?

Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.

How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.

Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.

Beneish M

Needs trade receivables, current assets, other expenses.

Cash vs profit

1.05× 6-year cumulative

Accruals are 4.4% of assets. Free cash flow negative in 2 of 6 years.

DuPont — return on equity FY2026

Net margin6.7%× Asset turnover1.47×× Leverage1.87×= ROE18.5%
What is this, and how do I read it?

DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.

Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.

Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.

How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.

Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.

Leverage & coverage FY2026

Debt / equity0.25×
Interest coverage15.00×
ROCE24.0%

Capital that builds FY2023 → FY2026

Capital deployed+3%
Revenue produced+33%
Still in CWIP₹47 cr

Revenue grew faster than the capital behind it, which is what operating leverage looks like: the existing asset base is working harder.

The formula notebook — every number above, worked out
Cash vs profit cumulative operating cash flow ÷ cumulative net profit ₹317 cr ÷ ₹302 cr, over 6 years 1.05× Above 1.0 means cash exceeds reported profit — the healthier reading.
Accruals (Sloan) (net profit − operating cash flow) ÷ average total assets (₹83 − ₹49) cr ÷ average assets 4.4% The share of profit that is accounting entries rather than cash. Above ~10% is where accruals start to dominate.
DuPont — return on equity net margin × asset turnover × leverage 6.7% × 1.47 × 1.87 18.5% Splits ROE into whether returns come from operations or from borrowing.
Interest coverage EBIT ÷ finance cost ₹120 cr ÷ ₹8 cr 15.00× How many times operating profit covers the interest bill.
Debt to equity borrowings ÷ net worth ₹111 cr ÷ ₹449 cr 0.25× Read against the sector — infrastructure carries more than software.
Capital that builds growth in fixed assets + CWIP, against growth in revenue capital +3% vs revenue +33%, FY2023 to FY2026 -30pp gap Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.

Going deepersame statements, harder questions

Montier C-Score

Needs more balance-sheet detail (only 3 of 6 flags testable).

Return on invested capital FY2026

ROIC16.1%
On new capital since FY2023 58.6%
Capital employed₹560 cr

NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.

What is this, and how do I read it?

Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.

ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?

NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.

How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.

Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.

Earnings quality ladder FY2026

Cash ÷ EBITDA0.35×
Cash ÷ profit0.59×
Free cash ÷ profit0.13×

Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.

What is this, and how do I read it?

The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.

Three ratios read in order, each stricter than the last.

Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.

How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.

Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.

What the price implies

51.8% free cash flow growth, every year for ten years

The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.

What is this, and how do I read it?

Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.

Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.

Discount rate
The return required for the risk taken. We use 11.5%, roughly the long-run cost of equity in India.
Terminal growth
Growth beyond the explicit ten years. We use 4%, near long-run nominal GDP.
The output
The free-cash-flow growth rate, every year for a decade, that makes the discounted total equal today's market value.

How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.

Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.

Cost of debt FY2026

Interest ÷ average borrowings7.51%
Average borrowings₹107 cr

Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.

What is this, and how do I read it?

Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.

What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.

Well below the policy rate
Suggests interest is being capitalised into assets rather than expensed, or that funding comes from related parties on non-market terms.
Near the policy rate plus a normal spread
Ordinary bank funding. Nothing to explain.
Well above
Lenders are pricing risk the equity market may not yet be.

How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.

Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.

Reading the numbers on this pagetwo bases, both shown

What the filings we hold do not give

Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.

Published screening frameworksrules applied, not opinions quoted

Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.

Graham — defensive investor

2 / 5
  • Debt below net worth ₹111 cr vs ₹449 cr
  • Positive earnings every year 6 of 6 years
  • Earnings growth over the period 0% since FY2022
  • P/E below 15 47.5×
  • P/E × P/B below 22.5 418.8

Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.

Greenblatt — magic formula

1 / 2
  • Return on capital above 20% 21.4%
  • Earnings yield above 8% 2.1%

Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.

O'Neil — CAN SLIM growth tests

4 / 4
  • Annual earnings growth above 25% 91%
  • Revenue growth above 20% 22%
  • Return on equity above 17% 18.5%
  • Share count not expanding equity capital ₹12 cr

The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.

Quality — compounder tests

4 / 4
  • Cash conversion above 0.9× 1.05× over 6 years
  • ROCE above 15% 24.0%
  • Interest covered more than 4× 15.00×
  • Debt below half of equity 0.25×

The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.

Against the sector28 companies

Median of the companies we hold in the same sector (Chemicals). Every figure on both sides is the live feed's trailing twelve months, so the two are measured the same way whatever depth of extraction this company has had. A number only means something next to something else — expensive against the market and cheap against peers are different facts.

P/E
47.5×
35.5×
+34%
P/B
8.8×
5.2×
+68%
Return on equity
17.5%
15.7%
+11%
Operating margin
9.7%
15.0%
-35%
Net margin
6.7%
10.9%
-38%
this companysector median

The page in pictures

Revenue and what it leaves behind

Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.

FY21 · 592FY21FY22 · 896FY22FY23 · 930FY23FY24 · 877FY24FY25 · 1,012FY25FY26 · 1,233FY26
Revenue (₹ cr)Net margin %

Where the year's cash went — FY2026

Operating cash first, then what the business spent and raised.

49Operating cash−42Investing0Financing

Quality over time

One year is a snapshot. These are the two lines that matter across a cycle.

7.24.72.2-0.2FY21FY22FY23FY24FY25FY26
Cash ÷ profit (×)ROCE (÷10)

Where cash gets stuck

Rising debtor or inventory days against flat sales is the earliest visible sign of stress.

15810553-0.4FY21FY22FY23FY24FY25FY26
Debtor daysInventory daysPayable daysCash cycle
Growth & valuation workspace

Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.

User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.

Valuation & quality

One canonical set of figures — the same numbers used everywhere else on this page and on the screener.

What you payHow the price compares with earnings, book and sales.
P/E (TTM)
47.5x
trailing 12m, live feed
P/B
8.81x
P/S
3.27x
PEG
2.43
What it earnsMargins and returns as the live feed reports them, on a rolling twelve months. The models above compute the same measures from the last audited statements, so the two can differ.
Operating margin
9.7%
trailing 12m, live feed
Net margin
6.7%
trailing 12m, live feed
Return on equity
17.5%
trailing 12m, live feed
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.25
conservative
Payout ratio
0.0%
Book value / share
₹75.4
Return on equity of 17.5% is built on a 6.7% net margin and debt of 0.25x equity. The full DuPont breakdown sits in the forensic models above.

Ownership & Skin in the Game

How the register has moved over recent quarters — the direction matters more than the level.

Promoter ― 0.00
Sep '2675.25%

Promoter held steady from 75.25% to 75.25% across these quarters.

FII ― 0.00
Sep '260.18%

FII held steady from 0.18% to 0.18% across these quarters.

MF ― 0.00
Sep '262.93%

MF held steady from 2.93% to 2.93% across these quarters.

Other ― 0.00
Sep '2621.64%

Other held steady from 21.64% to 21.64% across these quarters.

Working capital12-year series

Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.

MeasureFY2021FY2022FY2023FY2024FY2025FY2026
Debtor days
How long customers take to pay
907166677183
Inventory days
How long stock sits before it sells
688574587967
Payable days
How long the company takes to pay suppliers
143133919910291
Cash conversion cycle
Debtor + inventory − payable days
152249254858
Working capital days-25-75142842
ROCE %
Return on capital employed
32.0%15.0%11.0%15.0%24.0%
Trends

The shape of the business over time (annual) — read the direction, not the single print.

Revenue (₹ cr)
FY2021592FY2022896FY2023930FY2024877FY20251.0kFY20261.2k
Net profit (₹ cr)
FY202125.0FY202283.0FY202349.0FY202418.0FY202544.0FY202683.0

Annual Profit & Loss ₹ cr

LineFY2021FY2022FY2023FY2024FY2025FY2026
Revenue from operations5928969308771,0121,233
Other income972434
Depreciation131719212325
Finance cost1212121188
Profit before tax34111583459112
Net profit (owners)258349184483
EPS (₹)86.5214.248.383.137.5114.33

Exceptional items, total income and EBITDA are read from the filed statements.

Balance Sheet ₹ cr, annual

ItemFY2021FY2022FY2023FY2024FY2025FY2026
Equity Capital31212121212
Reserves177251298314356437
Borrowings16216218683102111
Net block267293291326326314
CWIP202560222147
Investments000000
Total Assets550677688626723839

Cash Flow ₹ cr

LineFY2021FY2022FY2023FY2024FY2025FY2026
Cash from operations2081291162249
Cash from investing-41-42-54-12-26-42
Cash from financing14-1211-115100
Free cash flow-2733-2397011
Net change in cash-728-13-1177

Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.

Disclosure & evidencewhat the filings actually show

These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.

Capital discipline

4 of 4 disclosed weighted 10 of 10
What was looked for
  • Profit converts to cash — 1.05× over 6 years
  • Free cash flow not persistently negative — 2 of 6 years negative
  • Capital converts into revenue — capital +3% vs revenue +33%
  • Interest comfortably covered — 15.00×

Others in Chemicals

The same read, applied to the companies this one competes with.

DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.
Chat on WhatsApp